44 results about "Antiinfective agent" patented technology

PCT No. PCT / US96 / 20932 Sec. 371 Date Jun. 30, 1998 Sec. 102(e) Date Jun. 30, 1998 PCT Filed Dec. 23, 1996 PCT Pub. No. WO97 / 25085 PCT Pub. Date Jul. 17, 1997The present invention relates to polymeric medical articles comprising the antiinfective agents chlorhexidine and triclosan. It is based, at least in part, on the discovery that the synergistic relationship between these compounds permits the use of relatively low levels of both agents, and on the discovery that effective antimicrobial activity may be achieved when these compounds are comprised in either hydrophilic or hydrophobic polymers. It is also based on the discovery that chlorhexidine free base and triclosan, used together, are incorporated into polymeric medical articles more efficiently. Medical articles prepared according to the invention offer the advantage of preventing or inhibiting infection while avoiding undesirably high release of antiinfective agent, for example into the bloodstream of a subject.

A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

The present invention relates to polymeric medical articles comprising the antiinfective agents chlorhexidine and triclosan. It is based, at least in part, on the discovery that the synergistic relationship between these compounds permits the use of relatively low levels of both agents, and on the discovery that effective antimicrobial activity may be achieved when these compounds are comprised in either hydrophilic or hydrophobic polymers.

Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

The invention provides semi-solid or liquid pharmaceutical compositions for topical administration to a finger- or toenail of a human. The compositions are useful for the delivery of active ingredients deep into the nail. Various active ingredients may be incorporated, such as antifungal agents, anti-infectives, anti-inflammatory agents, immunosuppressants, local anesthetics, and retinoids.

Compositions comprising DNase encapsulated in a liposome are provided. Additionally, provided are compositions comprising a free enzyme and empty liposomes, compositions comprising a free enzyme and an antiinfective encapsulated in a liposome, compositions comprising a free enzyme, a free-antiinfective, and empty liposomes, compositions comprising a free enzyme, a free antiinfective, and an antiinfective encapsulated in a liposome, and a composition comprising a free enzyme, empty liposomes, and an antiinfective encapsulated in a liposome, and compositions comprising a free enzyme, a free antiinfective, empty liposomes, an antiinfective encapsulated in a liposome, and pharmaceutical compositions comprising the aforementioned compositions. The Also provided are methods of treating pneumonia, bronchitis, cystic fibrosis, or emphysema comprising administering to a subject in need thereof a therapeutically effective amount of the aforementioned pharmaceutical composition.

The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], gro alpha [SEQ ID NO:2], gro beta [SEQ ID NO: 3] or gro gamma [SEQ ID NO: 4] or multimers thereof, alone or in conjunction with an anti-infective agent. This invention also relates to a new gro beta dimer chemokine.

The invention provides compounds and salts of Formula I and Formula II:which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula I and Formula II. The variables A1, A8, R2, R3, R5, R6, R7, and R9 are defined herein.Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of compounds of Formula I and / or Formula II and one or more other active agents. The invention also provides methods for treating microbial and protozoal infections in animals.

Sixteen membered macrolide anti-infective agents having a structure according to formula I where R1, R2, R3, R4, R5, and R6 are as defined herein, and related compounds are disclosed.

In one aspect of the invention, the antiinfective agents are flavonol compounds of the represented by formula I:Another aspect of the invention is a method for treating an infection in a subject by administering the compounds of Formula I to the subject.

One aspect of the invention relates to novel proanthocyandin compounds that are useful as antiinfective agents. In one embodiment, the invention relates to a pure and isolated compound of formula I or II:For example, compounds of the invention are useful antiviral agents against.Another aspect of the invention relates to methods of treating and infection, such as a viral infection, in a subject, comprising administering to the subject in need thereof the aforementioned compound

The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and / or into the wound of a patient.

The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I): wherein R1, R2, ect. Are defined in claim 1.

Described herein are methods and compositions related to biologic matrices comprising at least one anti-infective. In certain embodiments, the invention relates to a biologic matrix comprising a slowed release anti-infective agent. In a particular embodiment, the invention relates to an acellular dermal matrix comprising a slowed release antiinfective agent, wherein the anti-infective agent is triclosan. In further embodiments, the the biologic matrix is suitable for use in surgical procedures, such as, for example, for the replacement of damaged or inadequate integumental tissue or for the repair, reinforcement or supplemental support of soft tissue defects.

The present invention provides methods for the treatment or prevention of a viral, bacterial, or fungal infection using an anionic cellulose- or acrylic-based polymer, a prodrug thereof, or a pharmaceutically acceptable salt of said anionic cellulose based polymer or acrylic based polymer or prodrug of either. The present invention also provides pharmaceutical compositions comprising an anionic cellulose or acrylic based polymer, a prodrug thereof, or a pharmaceutically acceptable salt of said anionic cellulose-based polymer or prodrug. The present invention further provides combination therapies for the treatment or prevention of a viral, bacterial, or fungal infection using an anionic cellulose or acrylic-based polymer, a prodrug thereof, or a pharmaceutically acceptable salt of said anionic cellulose based or acrylic based polymer or prodrug of either and one or more anti-infective agents.

The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles, aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and / or anti-infective / antibiotic / anti-fungal agents, accepted as safe and efficacious for ophthalmic use.

The present invention relates to quinolinium antiinfective agents in which the qunolinium nucleus is fused to an indole ring or the qunolinium nucleus is linked to a cyclic structure through an opened indole or a benzothiophene or benzofuran ring. The compound is further substituted with various substituent groups.The compounds are represented by formula (I), (II) and (III):Pharmaceutical compositions and methods of use are also included.

A composition for treating, controlling, reducing, ameliorating, or alleviating infections and their inflammatory sequelae comprises a dissociated glucocorticoid receptor agonist (''DIGRA'') and an anti-infective agent, such as an antibacterial, antiviral, antifungal, antiprotozoal agent, or a combination thereof. The composition can be formulated for topical application, injection, or implantation.

The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.